This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Factor I [fibrinogen] deficiency제1인자[피브리노젠]의 결핍 (제일인자피브리노겐결핍증)

ItemDetails
A. Classification codesICD-10: D68.2 / Special Copayment Reduction: V009
B. SynonymsFibrinogen deficiency, Hypofibrinogenemia, Afibrinogenemia, Dysfibrinogenemia
C. Adult onsetNot low — mild hypofibrinogenemia and some dysfibrinogenemias are frequently first discovered after procedures in adulthood or through pregnancy complications
1. History2. Causes
3. Genetics4. General epidemiology
5. Pathophysiology6. Symptoms
7. Signs8. Screening
9. Diagnosis10. Treatment
11. Prognosis12. Prevention
13. References

1. History

Discovery of fibrinogen and early research

Fibrinogen is one of the oldest subjects of interest in the history of blood coagulation research. In 1859, as the German biochemist Rudolf Virchow systematized the theory of thrombus formation, the concept that plasma proteins are involved in coagulation began to be established, and Alexander Schmidt (1876) then identified fibrinogen as the precursor of fibrin. At that time, Schmidt was the first to describe the basic principle that cleavage of fibrinogen by thrombin induces fibrin polymerization, forming the foundation of coagulation research.

Clinical identification of congenital deficiency

The first clinical report of congenital fibrinogen deficiency was by Rabe and Salomon in 1920, who found that plasma fibrinogen was almost undetectable in a newborn with recurrent umbilical cord bleeding in whom ordinary hemostasis could not be achieved. Later, in 1955, when Ménaché introduced the concept of dysfibrinogenemia, it became known that, in addition to simple quantitative deficiency (afibrinogenemia/hypofibrinogenemia), fibrinogen variants with functional abnormalities exist.

The molecular biology era and modern classification

Since the 1980s, advances in molecular biology techniques revealed that the FGA, FGB and FGG genes form a cluster at chromosome 4q28. Since 2001, the International Society on Thrombosis and Haemostasis (ISTH) has systematized fibrinogen-related abnormalities into four types—afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia and hypodysfibrinogenemia—and the molecular causes of each type continue to be elucidated. More than 500 fibrinogen gene variants have been reported to date and are being compiled in a database (GEHT Fibrinogen Mutations Database).


2. Causes

Congenital causes: gene variants

Congenital fibrinogen deficiency is caused by variants in three genes: FGA (Aα chain), FGB (Bβ chain) and FGG (γ chain). Afibrinogenemia arises mainly from loss-of-function variants (nonsense, frameshift, splice-site) in both alleles, and no fibrinogen trimer (Aα-Bβ-γ) is produced at all. Hypofibrinogenemia arises from heterozygous loss-of-function variants or certain homozygous missense variants, and fibrinogen is reduced to below 20–150 mg/dL of the normal value. Dysfibrinogenemia mostly involves the production of a structurally abnormal protein due to missense variants; the antigen concentration is normal, but function is reduced or, conversely, becomes prothrombotic.

Acquired causes

Acquired fibrinogen reduction is seen more commonly in clinical practice. In disseminated intravascular coagulation (DIC), fibrinogen is rapidly depleted due to increased consumption, and in severe liver failure its synthesis in hepatocytes is reduced. In hyperfibrinolytic states (primary fibrinolysis, LVAD-related, after prostate cancer surgery), fibrinogen is also degraded prematurely, causing deficiency. Administration of L-asparaginase is a representative drug cause that selectively inhibits fibrinogen synthesis, and overuse of thrombolytics (t-PA, streptokinase) also causes acute hypofibrinogenemia.

Special clinical situations

Obstetric emergencies (amniotic fluid embolism, placental abruption, intrauterine fetal death) are well known to dramatically accelerate fibrinogen consumption. In these cases, fibrinogen levels can plunge below 100 mg/dL within a few hours, and dilutional hypofibrinogenemia from massive transfusion may also be present. Because fibrinogen physiologically increases to 400–600 mg/dL during pregnancy, caution is needed: a level of 200 mg/dL during pregnancy may look like the 'normal range' but may actually be abnormal.


3. Genetics

FGA, FGB and FGG cluster structure

The three chains that make up fibrinogen are encoded by the FGA (Aα chain, about 95 kDa), FGB (Bβ chain, about 56 kDa) and FGG (γ chain, about 47 kDa) genes, respectively. All three genes are clustered within a 50 kb range on chromosome 4q28. This arrangement allows coordinated regulation of gene expression, and they are expressed simultaneously in hepatocytes to form a hexamer ([AαBβγ]₂) in a 2:2:2 ratio.

Inheritance pattern and variant spectrum

Afibrinogenemia and hypofibrinogenemia follow an autosomal recessive inheritance pattern, while dysfibrinogenemia is mostly inherited in an autosomal dominant manner. Heterozygous carriers may have somewhat low fibrinogen antigen levels, but clinical symptoms are mild or absent. The most frequently reported variants include FGA c.510+1G>T (intron 4 splicing variant, afibrinogenemia), FGG p.Arg301His (dysfibrinogenemia, Fibrinogen Matsumoto I) and FGA p.Arg35His (Fibrinogen Detroit, thrombotic dysfibrinogenemia). Homozygous or compound heterozygous variants can cause serious bleeding from immediately after birth, while heterozygous dysfibrinogenemia may present with recurrent miscarriage, venous thrombosis or no symptoms.

Special features of hypodysfibrinogenemia

Hypodysfibrinogenemia is a combined form in which the amount of fibrinogen is reduced (hypo) and its function is also abnormal (dys), so the diagnosis cannot be reached by simple antigen measurement alone. In some variants, abnormal protein folding in the endoplasmic reticulum (ER) prevents normal secretion, leading to accumulation in hepatocytes, and cases accompanied by liver disease (liver fibrosis or cirrhosis) have been reported. In particular, the FGG p.Gly284Arg variant (Fibrinogen Aguadilla) is notable for a phenotype accompanied by liver fibrosis and a bleeding tendency.


4. General epidemiology

Prevalence and incidence

The overall prevalence of congenital fibrinogen deficiency is estimated worldwide at about 1 in 1 million. Afibrinogenemia is the rarest of these, with a prevalence of about 1 in 1 million to 1 in 2 million. The frequency of homozygous afibrinogenemia is reported to be relatively high in populations with high rates of consanguineous marriage, such as in Iran, southern Italy and parts of India. Dysfibrinogenemia is the most common type of all fibrinogen abnormalities, with more than 300 reported variant families; about 50% of these show a thrombotic tendency, about 25% a bleeding tendency, and the remaining 25% are asymptomatic.

Sex and age distribution

Congenital fibrinogen deficiency occurs equally in males and females (autosomal inheritance), with no particular sex bias. Afibrinogenemia tends to present early in the neonatal period and infancy with umbilical cord bleeding and intracranial hemorrhage, so it is often regarded as a pediatric disease. In contrast, hypofibrinogenemia and dysfibrinogenemia with a mild phenotype are not uncommonly first discovered in adulthood or later, especially in situations of hemostatic stress such as surgery, trauma, pregnancy and childbirth.

Situation in Korea

In Korea, patients with rare coagulation factor deficiencies can be identified indirectly through Special Copayment Reduction (V009) registration data from the Health Insurance Review & Assessment Service (HIRA), but domestic epidemiological data counting fibrinogen deficiency separately are limited. Because clinical practice does not routinely measure thrombin time (TT) or fibrinogen antigen levels in blood tests, many mild cases may be going undiagnosed.


5. Pathophysiology

Normal physiology of fibrinogen

Fibrinogen is a glycoprotein of about 340 kDa synthesized in hepatocytes and secreted into the blood, with a normal plasma concentration of 200–400 mg/dL. Thrombin cleaves fibrinopeptide A (FPA) and B (FPB) from the N-termini of the Aα and Bβ chains of fibrinogen, respectively, to form fibrin monomers, which polymerize to form a fibrin gel. Activated factor XIII (FXIIIa) then forms covalent cross-links between fibrin chains, completing a stable fibrin clot. Fibrinogen is also a multifunctional protein involved in platelet aggregation (GPIIb/IIIa receptor binding), inflammatory responses and wound healing.

Pathophysiology of deficiency and dysfunction

When fibrinogen is deficient, a fibrin gel cannot be made even when thrombin is formed, so a stable primary hemostatic plug does not form. In afibrinogenemia, the fibrinogen concentration is 0 mg/dL or unmeasurable, so serious bleeding occurs. In hypofibrinogenemia, when fibrinogen falls below 100 mg/dL, hemostasis after surgery and trauma is seriously impaired, and below 50 mg/dL the risk of spontaneous bleeding also increases. Interestingly, in some hypofibrinogenemias and dysfibrinogenemias, thrombosis occurs instead, because the dysfunctional fibrinogen interferes with normal fibrin degradation (fibrinolysis) or disrupts the protein C pathway, upsetting the anticoagulant balance.

Mechanism of the dual phenotype (bleeding-thrombosis)

There are three representative mechanisms by which a thrombotic phenotype appears in dysfibrinogenemia. First, the variant fibrin forms a dense fibrin network that hinders access of plasminogen activators and reduces fibrin degradation (e.g., Fibrinogen Dusart, Aα p.Arg554Cys). Second, the variant fibrinogen releases thrombin with abnormal delay, so the coagulation reaction persists. Third, in some variants, conventional D-dimer formation is hindered and intrinsic anticoagulant signaling is lacking. Thus, fibrinogen deficiency and dysfunction show a complex phenotypic spectrum beyond the framework of a simple 'bleeding disorder'.


6. Symptoms

Symptoms of afibrinogenemia

Patients with complete deficiency (afibrinogenemia) show serious bleeding symptoms from early life. The most typical initial symptom is umbilical cord bleeding; persistent bleeding after umbilical cord ligation immediately after birth strongly suggests this diagnosis. Later, intramuscular hematomas, mucosal bleeding (oral, nasal, gastrointestinal) and hemarthrosis occur, and the most lethal complication is intracranial hemorrhage (ICH). Spontaneous ICH can occur even without trauma and is a major cause of death in the neonatal period and infancy. In female patients, heavy menstrual bleeding, intrauterine hematoma during pregnancy and habitual miscarriage are characteristic symptoms.

Symptoms of hypofibrinogenemia

In hypofibrinogenemia (below 100–150 mg/dL), the main symptom is excessive bleeding in situations of hemostatic stress such as surgery, trauma and childbirth rather than spontaneous bleeding. Some patients are asymptomatic and are first diagnosed with placental hematoma, fetal growth restriction or early pregnancy loss during pregnancy. As a complex phenotype, thrombosis (deep vein thrombosis, pulmonary embolism) may not uncommonly accompany it, which is attributed to loss of the antithrombotic functions of fibrinogen (such as thrombin adsorption).

Symptoms of dysfibrinogenemia

The clinical phenotype of dysfibrinogenemia is diverse. In about 50% of variants, venous or arterial thrombosis is the main problem; about 25% show bleeding, and the remaining 25% are asymptomatic and found incidentally. The main sites of thrombus formation are the hepatic veins, mesenteric veins and pulmonary arteries, and cerebral venous sinus thrombosis has also been reported. The so-called mixed phenotype, in which bleeding and thrombosis occur together, makes treatment decisions particularly difficult.


7. Signs

Physical examination findings

The signs observed on physical examination in patients with fibrinogen deficiency vary with the degree of bleeding tendency. In severe deficiency, spontaneous petechiae, ecchymosis and mucosal bleeding are observed. With recurrent hemarthrosis, there may be joint deformity (especially of the ankle and knee). On abdominal palpation, hepatomegaly (in variants accompanied by liver fibrosis) or splenomegaly is rarely found. When thrombosis is present, physical signs of deep vein thrombosis such as leg swelling and redness may appear.

Laboratory abnormalities

Prolongation of the thrombin time (TT) is the most sensitive screening indicator, seen in both fibrinogen deficiency and dysfunction. TT is prolonged in proportion to the degree of fibrinogen deficiency, and TT is also prolonged in dysfibrinogenemia. When plasma fibrinogen function (Clauss method) measures lower than the antigen level, dysfibrinogenemia is suggested. Prothrombin time (PT) and activated partial thromboplastin time (aPTT) may also be prolonged when fibrinogen is very low but may be normal with mild reduction.

Imaging and pathology findings

When intracranial hemorrhage is suspected, brain CT or MRI shows an acute hematoma. Signs of liver fibrosis due to fibrinogen accumulation (increased echogenicity, irregular liver margins, etc.) are rarely found on liver ultrasound or MRI, and on liver biopsy, intrahepatocytic deposition of PAS-positive granules is characteristic. When thrombosis is present, the thrombus is identified on deep venous ultrasound or pulmonary CT angiography.


8. Screening

First-line screening tests

Screening for fibrinogen deficiency is performed with the thrombin time (TT) and plasma fibrinogen quantification (Clauss method). TT is a test that measures the rate of fibrin polymerization by directly adding thrombin rather than through a calcium-dependent coagulation reaction, and it is prolonged when the fibrinogen concentration is low or function is abnormal. Measurement of fibrinogen function by the Clauss method, which back-calculates the fibrinogen concentration from the clotting time, is the clinical standard. Comparing antigen levels (ELISA or nephelometry) with functional levels (Clauss method) can determine whether there is a functional abnormality.

Confirmatory and special tests

When TT is prolonged, also performing the reptilase time can distinguish whether heparin is having an effect (heparin prolongs TT but does not prolong the reptilase time). When reduced fibrinogen function is confirmed, real-time coagulation kinetics are assessed with fibrin polymerization tests and viscoelastic coagulation tests (TEG, ROTEM). In ROTEM, fibrinogen deficiency markedly reduces the amplitude (A10, A20) of the FIBTEM assay. Genetic analysis (NGS-based coagulation panel or whole-genome analysis) is used to identify the type of variant and the inheritance pattern.

Screening of obstetric risk groups

Screening for fibrinogen deficiency during pregnancy is needed when there is a history of recurrent miscarriage, a history of excessive bleeding in a previous pregnancy or a family history. Normal fibrinogen levels in the third trimester show a physiological increase to 400–600 mg/dL, so a level below 200 mg/dL during pregnancy is considered low by pregnancy standards. Fibrinogen monitoring during pregnancy is useful for assessing bleeding risk in high-risk pregnancies.


9. Diagnosis

Diagnostic criteria

Congenital fibrinogen deficiency is confirmed along three axes: clinical symptoms, laboratory findings and genetic analysis. The diagnostic criteria for afibrinogenemia are a functional fibrinogen level (Clauss method) below 100 mg/dL (or unmeasurable), infinitely prolonged TT and reptilase time, and undetectable or markedly reduced fibrinogen antigen. Hypofibrinogenemia is defined as a functional fibrinogen level below 100–150 mg/dL. Dysfibrinogenemia is defined as a functional:antigenic ratio <0.7, and the variant is confirmed by genetic analysis.

Differential diagnosis

When TT prolongation is confirmed, the following must be differentiated: use of heparin or direct thrombin inhibitors (DTI) (compare with the reptilase time), DIC (accompanied by elevated D-dimer, elevated FDP and thrombocytopenia), liver failure (abnormal liver function tests such as PT, albumin and ALT), primary hyperfibrinolysis (reduced alpha2-antiplasmin), and anti-fibrinogen autoantibodies (acquired dysfibrinogenemia). In DIC, fibrinogen decreases progressively, accompanied by a sharp rise in D-dimer and FDP.

Genetic counseling

Genetic counseling is recommended for confirmed patients and their families. For siblings of patients with afibrinogenemia, carrier testing for homozygous or compound heterozygous variants is considered. In dysfibrinogenemia, autosomal dominant inheritance is possible, so testing of first-degree relatives is recommended. For patients planning pregnancy, the possibility of preimplantation genetic diagnosis (PGT) or prenatal diagnosis should be fully explained.


10. Treatment

Fibrinogen concentrate

Currently the most preferred treatment is intravenous administration of fibrinogen concentrate (e.g., Haemocomplettan, RiaSTAP). The dose is calculated considering the target fibrinogen level (in afibrinogenemia, a target of 100 mg/dL or higher for prophylaxis and 150–200 mg/dL or higher for surgery) and the volume of distribution (plasma fibrinogen volume of distribution about 40 mL/kg, recovery about 70%). In adults, about 30–50 mg of fibrinogen concentrate per kg of body weight raises the fibrinogen level by about 80–100 mg/dL. The half-life is about 3–4 days, and prophylactic administration is given at 2–3-week intervals.

Fresh frozen plasma (FFP) and cryoprecipitate

When fibrinogen concentrate is unavailable, fresh frozen plasma (FFP) or cryoprecipitate is an alternative. Cryoprecipitate contains about 150–250 mg of fibrinogen per unit and can supply fibrinogen without large-volume administration, so it can be used as a substitute for fibrinogen concentrate. FFP alone requires very large volumes to correct fibrinogen (risk of volume overload), so its use alone is limited. In terms of the risk of transfusion-transmitted infection, pathogen-inactivated fibrinogen concentrate is the safest choice.

Treatment of thrombotic dysfibrinogenemia

In patients with dysfibrinogenemia with a thrombotic tendency, anticoagulant therapy rather than bleeding treatment becomes the main treatment goal. After an acute thrombotic event, low-molecular-weight heparin or oral anticoagulants (vitamin K antagonists or direct oral anticoagulants, DOAC) are used, and long-term anticoagulant therapy is considered when there is recurrent thrombosis. In patients with a mixed bleeding and thrombotic tendency, the choice of treatment is extremely difficult, so thorough consultation with a hematologist is essential.


11. Prognosis

Prognosis of afibrinogenemia

Without appropriate prophylactic fibrinogen replacement, the main cause of death in patients with afibrinogenemia is intracranial hemorrhage. In the past, mortality from ICH in infancy was high, but in developed countries where the availability of fibrinogen concentrate has expanded, long-term survival is becoming possible through prophylactic administration. The long-term course over 10–20 years or more in patients receiving prophylaxis may not differ greatly from that of the general population, but the risk of spontaneous intracranial hemorrhage still remains.

Prognosis of hypofibrinogenemia and dysfibrinogenemia

Patients with mild hypofibrinogenemia can lead a normal life with only appropriate follow-up and preoperative preventive measures. The prognosis of dysfibrinogenemia differs greatly by phenotype. Patients with the thrombotic phenotype may have high long-term morbidity, such as reduced cardiopulmonary function and post-stroke sequelae, from recurrent thrombotic events. In certain variants accompanied by hepatic deposition, there is a possibility of progression to cirrhosis, so regular liver function monitoring is needed.

Pregnancy and obstetric prognosis

Pregnancy in women with afibrinogenemia is very dangerous without fibrinogen replacement, and maintaining a natural pregnancy has traditionally been very difficult. However, successful deliveries with regular prophylactic fibrinogen concentrate have been reported. Maintaining target fibrinogen levels during pregnancy (150 mg/dL or higher in the first trimester, 200 mg/dL or higher in the second and third trimesters) can markedly reduce obstetric complications.


12. Prevention

Prophylactic fibrinogen replacement therapy

In patients with afibrinogenemia, regular prophylactic administration of fibrinogen concentrate is recommended to prevent bleeding events. According to the European Haemophilia Network (EHN) and International Society on Thrombosis and Haemostasis (ISTH) guidelines, the target fibrinogen trough level is 50–100 mg/dL or higher. The prophylactic dosing interval is usually 1–3 weeks, adjusted to the individual's fibrinogen half-life and bleeding risk. In patients with hypofibrinogenemia, preemptive administration (on-demand prophylaxis) is planned ahead of risk situations (surgery, childbirth, trauma).

Management during surgery and invasive procedures

The preoperative fibrinogen target varies with symptoms and type of surgery, but 150–200 mg/dL or higher is generally recommended. For major surgery, fibrinogen monitoring before, during and after surgery and additional administration as needed are essential. Real-time fibrinogen assessment with ROTEM in the operating room enables tailored replacement therapy. Prior consultation with a hematology specialist is recommended before all invasive procedures, including dental procedures.

Genetic counseling and family screening

Screening of the immediate family of confirmed patients can identify asymptomatic patients with mild deficiency early. In communities where consanguineous marriage is common, expanding carrier testing can help prevent the birth of newborns with homozygous severe deficiency. Confirmed patients need education on avoiding sports with a high bleeding risk (combat sports, contact sports), taking care to avoid head injury, and how to obtain immediate medical care when symptoms suggesting ICH, such as headache, occur.


13. References

  1. de Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders. Semin Thromb Hemost. 2009;35(4):356-366.
  2. Casini A, Blondon M, Lebreton A, et al. Natural history of patients with congenital dysfibrinogenemia. Blood. 2015;125(3):553-561.
  3. Neerman-Arbez M, de Moerloose P, Casini A. Laboratory and genetic investigation of mutations accounting for congenital fibrinogen disorders. Semin Thromb Hemost. 2016;42(4):356-365.
  4. Peyvandi F, Palla R, Menegatti M, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost. 2012;10(4):615-621.
  5. Margaglione M, Grandone E. Population genetics of venous thromboembolism. A narrative review. Thromb Haemost. 2011;105(2):221-231.
  6. Bolliger D, Görlinger K, Tanaka KA. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology. 2010;113(5):1205-1219.
  7. Mackie IJ, Kitchen S, Machin SJ, et al. Guidelines on fibrinogen assays. Br J Haematol. 2003;121(3):396-404.
  8. Levy JH, Welsby I, Goodnough LT. Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. Transfusion. 2014;54(5):1389-1405.
  9. Franchini M, Mannucci PM. Congenital coagulation disorders: an update. Thromb Haemost. 2010;104(3):444-451.
  10. Simurda T, Asselta R, Zapletal O, et al. Congenital afibrinogenemia and hypofibrinogenemia: laboratory and genetic testing in families with identified mutations and novel mutations in the fibrinogen gene cluster. Diagnostics (Basel). 2020;10(12):1033.
  11. Casini A, de Moerloose P, Neerman-Arbez M. Clinical features and management of congenital fibrinogen deficiencies. Semin Thromb Hemost. 2016;42(4):366-374.
  12. Reininger AJ. Function of von Willebrand factor in haemostasis and thrombosis. Haemophilia. 2008;14(Suppl 5):11-26.